0F
0FY.F Equillium Inc
- Market cap
- EUR 97.2M
- P/E
- -
- P/B
- 2.07x
- ROE
- -35.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0FY.F undervalued?
Graham numberThe Graham number of Equillium Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Equillium Inc fundamental analysis
No fundamental analysis for Equillium Inc yet.
Equillium Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was…
Full company profileEquillium Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Equillium Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 15.8M | 36.1M | 41.1M | 0.00 | 0.00 |
| Operating Income | - | -8.62M | -26.7M | -29.5M | -37.8M | -39.0M | -14.5M | -8.27M | -23.6M | -21.5M |
| EBITDA | - | -10.7M | -25.3M | -28.7M | - | -61.3M | -12.1M | -8.13M | -23.5M | -21.4M |
| Net Income | - | -13.3M | -25.6M | -29.8M | -39.1M | -62.4M | -13.3M | -8.07M | -22.4M | -20.0M |
| EPS | - | -0.76 | -1.47 | -1.20 | -1.33 | -1.81 | -0.38 | -0.23 | -0.36 | -0.32 |
| Balance Sheet | ||||||||||
| Total Assets | 7.15M | 67.2M | 55.5M | 85.4M | 85.4M | 78.4M | 50.5M | 25.6M | 31.9M | 58.7M |
| Total Liabilities | 9.40M | 2.23M | 13.7M | 15.6M | 18.9M | 46.5M | 28.0M | 6.54M | 3.29M | 2.65M |
| Shareholders' Equity | -2.25M | 64.9M | 41.8M | 69.9M | 66.5M | 31.9M | 22.6M | 19.1M | 28.6M | 56.0M |
| Cash & Short-term Investments | 7.10M | 28.5M | 13.2M | 24.0M | 50.4M | 59.1M | 23.2M | 18.1M | 30.3M | 57.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -795K | -7.53M | -22.9M | -24.6M | -32.1M | -8.73M | -21.8M | -19.0M | -22.7M | -16.8M |
| Capital Expenditure | 2.64K | 35.0K | 74.0K | 202K | 57.0K | 279K | 50.0K | 85.0K | 48.0K | 148K |
| Free Cash Flow | - | -7.56M | -23.0M | -24.8M | -32.1M | -9.01M | -21.8M | -19.1M | -22.8M | -17.0M |
| Ratios | ||||||||||
| ROE | - | -20.4% | -61.2% | -42.7% | -58.7% | -195.4% | -59.1% | -42.3% | -78.3% | -35.7% |
| ROA | - | -19.7% | -46.1% | -34.9% | -45.7% | -79.6% | -26.4% | -31.5% | -70.2% | -34.1% |
| Net Profit Margin | - | - | - | - | - | -396.1% | -37.0% | -19.6% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Equillium Inc dividends
Equillium Inc has not paid dividends in the last 9 fiscal years.
Who owns Equillium Inc
- Insiders 16.00%
- Institutions 67.78%
- Public & others 16.22%
- Shares outstanding 78.4M
- Free float 47.9M
Equillium Inc company profile
- Company name
- Equillium Inc
- Ticker
- 0FY.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
- Phone
- 858 240 1200
- Website
- equilliumbio.com
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Equillium Inc management
5- Mr. Bruce SteelCo-Founder, CEO & Director · born 1966
- Dr. Stephen Connelly Ph.D.Chief Scientific Officer & President · born 1981
- Ms. Christine Zedelmayer M.B.A., P.M.P.Senior VP & COO · born 1970
- Ms. Penny Tom CPASenior VP of Finance & Principal Accounting Officer
- Mr. Michael MooreVice President of Investor Relations & Corporate Communications